Raymond James & Associates Hutchmed (China) LTD Transaction History

Raymond James & Associates

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$8.59 - $20.77 $431,973 - $1.04 Million	-50,288 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$15.52 - $35.65 $67,527 - $155,113	4,351 Added 9.47%	50,288 $951,000
Q4 2021 Feb 08, 2022	BUY	$28.89 - $35.33 $41,283 - $50,486	1,429 Added 3.21%	45,937 $1.61 Million
Q3 2021 Nov 02, 2021	BUY	$35.66 - $42.94 $143,388 - $172,661	4,021 Added 9.93%	44,508 $1.63 Million
Q2 2021 Aug 11, 2021	BUY	$23.7 - $39.27 $620,063 - $1.03 Million	26,163 Added 182.65%	40,487 $1.59 Million
Q1 2021 May 14, 2021	BUY	$27.01 - $36.8 $34,923 - $47,582	1,293 Added 9.92%	14,324 $405,000
Q4 2020 Feb 12, 2021	BUY	$27.51 - $34.36 $24,566 - $30,683	893 Added 7.36%	13,031 $417,000
Q3 2020 Nov 04, 2020	BUY	$25.8 - $34.61 $30,727 - $41,220	1,191 Added 10.88%	12,138 $392,000
Q2 2020 Jul 28, 2020	BUY	$17.65 - $28.05 $193,214 - $307,063	10,947 New	10,947 $302,000

6.77M

8.2K

9.2K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $2.75B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.